MicroRNA-181a regulates local immune balance by inhibiting proliferation and immunosuppressive properties of mesenchymal stem cells

Stem Cells

Volumn 30, Issue 8, 2012, Pages 1756-1770

  Liu, Liu ^a   Wang, Yaping ^a   Fan, Hongye ^a   Zhao, Xiaoyin ^a   Liu, Dan ^a   Hu, Yali ^b   Kidd III, Ambrose R ^c   Bao, Jianxin ^c   Hou, Yayi ^a  

^a NANJING UNIVERSITY   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

IL 6; MAPK; Mesenchymal stem cells; MiR 181a; TGF

Indexed keywords

DEXTRAN SULFATE; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 6; MESSENGER RNA; MICRORNA; MICRORNA 181A; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; COLITIS; CONTROLLED STUDY; DECIDUA; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PREECLAMPSIA; PROTEIN EXPRESSION; RNA ANALYSIS; T LYMPHOCYTE; UMBILICAL CORD; UNTRANSLATED REGION;

ANIMALS; CELL GROWTH PROCESSES; DISEASE MODELS, ANIMAL; HUMANS; INTERLEUKIN-6; MESENCHYMAL STROMAL CELLS; MICE; MICRORNAS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84864330589     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1156     Document Type: Article

References (74)

1. Alfaro MP, Vincent A, Saraswati S et al. sFRP2 suppression of bone morphogenic protein (BMP) and Wnt signaling mediates mesenchymal stem cell (MSC) self-renewal promoting engraftment and myocardial repair. J Biol Chem 2010;285:35645-35653.
2. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815-1822. (Pubitemid 40223708)
3. Aicher A, Brenner W, Zuhayra M et al. Assessment of the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling. Circulation 2003;107:2134-2139. (Pubitemid 36532196)
4. Picinich SC, Mishra PJ, Mishra PJ et al. The therapeutic potential of mesenchymal stem cells. Expert Opin Biol Ther 2007;7:965-973. (Pubitemid 47204355)
5. Sun L, Wang D, Liang J et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum 2010;62:2467-2475.
6. Sun L, Akiyama K, Zhang H et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009;27:1421-1432.
7. Zhang Q, Shi S, Liu Y et al. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J Immunol 2009;183:7787-7798.
8. Zhou CC, Zhang YJ, Irani RA et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med 2008; 14:855-862.
9. Kanasaki K, Kalluri R. The biology of preeclampsia. Kidney Int 2009;76:831-837.
10. Goldman-Wohl DS, Yagel S. Examination of distinct fetal and maternal molecular pathways suggests a mechanism for the development of preeclampsia. J Reprod Immunol 2007;76:54-60. (Pubitemid 350100879)
11. Cutler AJ, Limbani V, Girdlestone J et al. Umbilical cord-derived mesenchymal stromal cells modulate monocyte function to suppress T cell proliferation. J Immunol 2010;185:6617-6623.
12. Atkinson K, Chatterjee K, Barlow S et al. Potential for mesenchymal stem cell isolation from human placenta. Blood 2005;106:158b-158b.
13. Schwab KE, Gargett CE. Co-expression of two perivascular cell markers isolates mesenchymal stem-like cells from human endometrium. Hum Reprod 2007;22:2903-2911. (Pubitemid 351709405)
14. Hwang JH, Lee MJ, Seok OS et al. Cytokine expression in placenta-derived mesenchymal stem cells in patients with pre-eclampsia and normal pregnancies. Cytokine 2010;49:95-101.
15. Benian A, Uzun H, Aydin S et al. Placental stem cell markers in preeclampsia. Int J Gynaecol Obstet 2008;100:228-233. (Pubitemid 351258098)
16. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001;294:862-864. (Pubitemid 33032105)
17. Lai EC. Micro RNAs are complementary to 30 UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet 2002; 30:363-364.
18. Hu YL, Li PF, Hao S et al. Differential expression of microRNAs in the placentae of Chinese patients with severe pre-eclampsia. Clin Chem Lab Med 2009;47:923-929.
19. Mayor-Lynn K, Toloubeydokhti T, Cruz AC et al. Expression profile of MicroRNAs and mRNAs in human placentas from pregnancies complicated by preeclampsia and preterm labor. Reprod Sci 2011;18: 46-56.
20. Zhu XM, Han T, Sargent IL et al. Differential expression profile of microRNAs in human placentas from preeclamptic pregnancies vs normal pregnancies. Am J Obstet Gynecol 2009; 200.
21. Li QJ, Chau J, Ebert PJR et al. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 2007;129:147-161. (Pubitemid 46507589)
22. Liu G, Min HY, Yue SB et al. Pre-miRNA loop nucleotides control the distinct activities of mir-181a-1 and mir-181c in early T cell development. PLoS One 2008; 3.
23. Ebert PJR, Jiang S, Xie JM et al. An endogenous positively selecting peptide enhances mature T cell responses and becomes an autoantigen in the absence of microRNA miR-181a. Nat Immunol 2009;10: 1162-1169.
24. Debernardi S, Skoulakis S, Molloy G et al. MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis. Leukemia 2007;21:912-916. (Pubitemid 46672066)
25. Zhu DX, Miao KR, Fang C et al. Aberrant microRNA expression in Chinese patients with chronic lymphocytic leukemia. Leukemia Res 2011;35:730-734.
26. Gao W, Yu Y, Cao HL et al. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother 2010;64:399-408.
27. Bellon M, Lepelletier Y, Hermine O et al. Deregulation of microRNA involved in hematopoiesis and the immune response in HTLV-I adult T-cell leukemia. Blood 2009;113:4914-4917.
28. Chen G, Zhu W, Shi DZ et al. MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2. Oncol Rep 2010;23:997-1003.
29. Shin KH, Bae SD, Hong HS et al. miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras. Biochem Biophys Res Commun 2011;404:896-902.
30. Shi L, Cheng ZH, Zhang JX et al. hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. Brain Res 2008; 1236:185-193.
31. Xie H, Hua C, Sun L et al. 17beta-estradiol induces CD40 expression in dendritic cells via MAPK signaling pathways in a minichromosome maintenance protein 6-dependent manner. Arthritis Rheum 2011;63: 2425-2435.
32. Zhang QZ, Shi SH, Liu Y et al. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis (vol 183, pg 7787, 2009). J Immunol 2010;184:1656.
33. Zenclussen AC, Fest S, Joachim R et al. Introducing a mouse model for pre-eclampsia: Adoptive transfer of activated Th1 cells leads to pre-eclampsia-like symptoms exclusively in pregnant mice. Eur J Immunol 2004;34:377-387. (Pubitemid 39255948)
34. Maby-El Hajjami H, Ame-Thomas P, Pangault C et al. Functional alteration of the lymphoma stromal cell niche by the cytokine context: Role of indoleamine-2,3 dioxygenase. Cancer Res 2009;69: 3228-3237.
35. Yang YH, Toh ML, Clyne CD et al. Annexin 1 negatively regulates IL-6 expression via effects on p38 MAPK and MAPK phophatase-1. J Immunol 2006;177:8148-8153. (Pubitemid 44846334)
36. Sappington RM, Calkins DJ. Pressure-induced regulation of IL-6 in retinal glial cells: Involvement of the ubiquitin/proteasome pathway and NF kappa B. Invest Ophthalmol Vis Sci 2006;47:3860-3869. (Pubitemid 46044301)
37. Jeong YI, Kim SW, Jung ID et al. Curcumin suppresses the induction of indoleamine 2,3-dioxygenase by blocking the Janus-activated kinase-protein kinase C delta-STAT1 signaling pathway in interferongamma-stimulated murine dendritic cells. J Biol Chem 2009;284: 3700-3708.
38. Fujigaki H, Saito K, Fujigaki S et al. The signal transducer and activator of transcription 1 alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: Involvement of p38 mitogen-activated protein kinase and nuclear Factor-kappa B pathways, and synergistic effect of several proinflammatory cytokines. J Biochem 2006;139: 655-662. (Pubitemid 43973911)
39. Jung ID, Lee CM, Jeong YI et al. Differential regulation of indoleamine 2,3-dioxygenase by lipopolysaccharide and interferon gamma in murine bone marrow derived dendritic cells. FEBS Lett 2007;581: 1449-1456. (Pubitemid 46463960)
40. Andoh A, Bamba S, Fujiyama Y et al. Colonic subepithelial myofibroblasts in mucosal inflammation and repair: Contribution of bone marrow- derived stem cells to the gut regenerative response. J Gastroenterol 2005;40:1089-1099. (Pubitemid 43124835)
41. Yabana T, Arimura Y, Tanaka H et al. Enhancing epithelial engraftment of rat mesenchymal stem cells restores epithelial barrier integrity. J Pathol 2009;218:350-359.
42. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003;425:577-584. (Pubitemid 37280136)
43. Yoshimura A, Wakabayashi Y, Mori T. Cellular and molecular basis for the regulation of inflammation by TGF-beta. J Biochem 2010;147: 781-792.
44. Moustakas A, Pardali K, Gaal A et al. Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunol Lett 2002;82:85-91. (Pubitemid 34468039)
45. Runyan CE, Poncelet AC, Schnaper HW. TGF-beta receptor-binding proteins: Complex interactions. Cell Signal 2006;18:2077-2088. (Pubitemid 44636159)
46. Miettinen PJ, Ebner R, Lopez AR et al. Tgf-Beta induced transdifferentiation of mammary epithelial-cells to mesenchymal cells-Involvement of type-I receptors. J Cell Biol 1994;127:2021-2036.
47. Jian HY, Shen X, Liu I et al. Smad3-dependent nuclear translocation of beta-catenin is required for TGF-beta 1-induced proliferation of bone marrow-derived adult human mesenchymal stem cells. Gene Dev 2006;20:666-674.
48. Dong M, Blobe GC. Role of transforming growth factor-beta in hematologic malignancies. Blood 2006;107:4589-4596. (Pubitemid 43882602)
49. Wurthner JU, Frank DB, Felici A et al. Transforming growth factor-beta receptor-associated protein 1 is a Smad4 chaperone. J Biol Chem 2001;276:19495-19502.
50. Thompson K, Hamilton DW, Leask A. ALK5 inhibition blocks TGFβ-induced CCN2 expression in gingival fibroblasts. J Dent Res 2010;89:1450-1454.
51. Bandyopadhyay B, Han A, Dai J et al. TbetaRI/Alk5-independent TbetaRII signaling to ERK1/2 in human skin cells according to distinct levels of TbetaRII expression. J Cell Sci 2011;124:19-24.
52. Pannu J, Gore-Hyer E, Yamanaka M et al. An increased transforming growth factor beta receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor beta receptor type II in scleroderma. Arthritis Rheum 2004;50:1566-1577. (Pubitemid 38608079)
53. Chen CZ, Li L, Lodish HF et al. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004;303:83-86. (Pubitemid 38055775)
54. Krampera M, Cosmi L, Angeli R et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006;24:386-398. (Pubitemid 44464808)
55. Meisel R, Zibert A, Laryea M et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004;103:4619-4621. (Pubitemid 38745993)
56. Zhao SM, Wehner R, Bornhauser M et al. Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders. Stem Cells Dev 2010;19:607-614.
57. Shi YF, Hu GZ, Su JJ et al. Mesenchymal stem cells: A new strategy for immunosuppression and tissue repair. Cell Res 2010;20:510-518.
58. Gieseke F, Schutt B, Viebahn S et al. Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFN gamma R1 signaling and IDO expression. Blood 2007;110: 2197-2200. (Pubitemid 47443941)
59. Jones SA. Directing transition from innate to acquired immunity: Defining a role for IL-6. J Immunol 2005;175:3463-3468. (Pubitemid 41292002)
60. Eddahri F, Denanglaire S, Bureau F et al. Interleukin-6/STAT3 signaling regulates the ability of naive T cells to acquire B-cell help capacities. Blood 2009;113:2426-2433.
61. Jiang XX, Zhang Y, Liu B et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005;105:4120-4126. (Pubitemid 40656164)
62. Nauta AJ, Kruisselbrink AB, Lurvink E et al. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte- derived dendritic cells. J Immunol 2006;177:2080-2087. (Pubitemid 44200965)
63. Spaggiari GM, Abdelrazik H, Becchetti F et al. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: Central role of MSC-derived prostaglandin E2. Blood 2009;113:6576-6583.
64. Li YP, Paczesny S, Lauret E et al. Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway. J Immunol 2008;180:1598-1608.
65. Najar M, Rouas R, Raicevic G et al. Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: The importance of low cell ratio and role of interleukin-6. Cytotherapy 2009;11:570-583.
66. Bermudez O, Pages G, Gimond C. The dual-specificity MAP kinase phosphatases: Critical roles in development and cancer. Am J Physiol-Cell Physiol 2010;299:C189-C202.
67. Zhang J, Mendoza M, Guiraldelli MF et al. Small interfering RNA screen for phosphatases involved in IgE-mediated mast cell degranulation. J Immunol 2010;184:7178-7185.
68. Toledano-Katchalski H, Kraut J, Sines T et al. Protein tyrosine phosphatase epsilon inhibits signaling by mitogen-activated protein kinases. Mol Cancer Res 2003;1:541-550. (Pubitemid 36577049)
69. Scharl M, McCole DF, Weber A et al. Protein tyrosine phosphatase N2 regulates TNFalpha-induced signalling and cytokine secretion in human intestinal epithelial cells. Gut 2011;60:189-197.
70. Han S, Williams S, Mustelin T. Cytoskeletal protein tyrosine phosphatase PTPH1 reduces T cell antigen receptor signaling. Eur J Immunol 2000;30:1318-1325. (Pubitemid 30311960)
71. Shaarawy M, Zaki S, Ramzi AM et al. Feto-maternal bone remodeling in normal pregnancy and preeclampsia. J Soc Gynecol Invest 2005;12: 343-348. (Pubitemid 40848458)
72. Wang Y, Lewis DF, Gu Y et al. Elevated maternal soluble Gp130 and IL-6 levels and reduced Gp130 and SOCS-3 expressions in women complicated with preeclampsia. Hypertension 2011;57:336-342.
73. Benyo DF, Smarason A, Redman CW et al. Expression of inflammatory cytokines in placentas from women with preeclampsia. J Clin Endocrinol Metab 2001;86:2505-2512. (Pubitemid 32545699)
74. Benyo DF, Miles TM, Conrad KP. Hypoxia stimulates cytokine production by villous explants from the human placenta. J Clin Endocrinol Metab 1997;82:1582-1588. (Pubitemid 27200438)